These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort. Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105 [TBL] [Abstract][Full Text] [Related]
5. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients. Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660 [TBL] [Abstract][Full Text] [Related]
6. Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. Kovacs KD; Patel S; Orlin A; Kim K; Van Everen S; Conner T; Sondhi D; Kaminsky SM; D'Amico DJ; Crystal RG; Kiss S Ophthalmol Retina; 2020 Jul; 4(7):728-736. PubMed ID: 32146219 [TBL] [Abstract][Full Text] [Related]
13. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series. Wibbeler E; Wang R; Reyes EL; Specchio N; Gissen P; Guelbert N; Nickel M; Schwering C; Lehwald L; Trivisano M; Lee L; Amato G; Cohen-Pfeffer J; Shediac R; Leal-Pardinas F; Schulz A J Child Neurol; 2021 May; 36(6):468-474. PubMed ID: 33356800 [TBL] [Abstract][Full Text] [Related]
14. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease. Hammon K; de Hart G; Vuillemenot BR; Kennedy D; Musson D; O'Neill CA; Katz ML; Henshaw JW Clin Transl Sci; 2021 Sep; 14(5):1810-1821. PubMed ID: 34076336 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study. Cherukuri A; Cahan H; de Hart G; Van Tuyl A; Slasor P; Bray L; Henshaw J; Ajayi T; Jacoby D; O'Neill CA; Schweighardt B Clin Immunol; 2018 Dec; 197():68-76. PubMed ID: 30205177 [TBL] [Abstract][Full Text] [Related]
16. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657 [TBL] [Abstract][Full Text] [Related]
17. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report. Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290 [TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105 [TBL] [Abstract][Full Text] [Related]
19. Cerliponase Alfa: First Global Approval. Markham A Drugs; 2017 Jul; 77(11):1247-1249. PubMed ID: 28589525 [TBL] [Abstract][Full Text] [Related]
20. Assessment of inner and outer retinal layer metrics on the Cirrus HD-OCT Platform in normal eyes. Arepalli S; Srivastava SK; Hu M; Kaiser PM; Dukles N; Reese JL; Ehlers JP PLoS One; 2018; 13(10):e0203324. PubMed ID: 30286099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]